» Articles » PMID: 39355923

Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis

Overview
Journal Circulation
Date 2024 Oct 2
PMID 39355923
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several sham-controlled trials have investigated the efficacy and safety of catheter-based renal denervation (RDN) with mixed outcomes. We aimed to perform a comprehensive meta-analysis of all randomized, sham-controlled trials investigating RDN with first- and second-generation devices in hypertension.

Methods: We searched MEDLINE and the Cochrane Library for eligible trials. Outcomes included both efficacy (24-hour and office systolic [SBP] and diastolic blood pressure [DBP]) and safety (all-cause death, vascular complication, renal artery stenosis >70%, hypertensive crisis) of RDN. We performed a study-level, pairwise, random-effects meta-analysis of the summary data.

Results: Ten trials comprising 2478 patients with hypertension while being either off or on treatment were included. Compared with sham, RDN reduced 24-hour and office systolic blood pressure by 4.4 mm Hg (95% CI, 2.7 to 6.1; <0.00001) and 6.6 mm Hg (95% CI, 3.6 to 9.7; <0.0001), respectively. The 24-hour and office diastolic blood pressure paralleled these findings (-2.6 mm Hg [95% CI, -3.6 to -1.5]; <0.00001; -3.5 mm Hg [95% CI, -5.4 to -1.6]; =0.0003). There was no difference in 24-hour and office systolic blood pressure reduction between trials with and without concomitant antihypertensive medication ( for interaction, 0.62 and 0.73, respectively). There was no relevant difference in vascular complications (odds ratio, 1.69 [95% CI, 0.57 to 5.0]; =0.34), renal artery stenosis (odds ratio, 1.50 [95% CI, 0.06 to 36.97]; =0.80), hypertensive crisis (odds ratio, 0.65 [95% CI, 0.30 to 1.38]; =0.26), and all-cause death (odds ratio, 1.76 [95% CI, 0.34 to 9.20]; =0.50) between RDN and sham groups. Change of renal function based on estimated glomerular filtration rate was comparable between groups ( for interaction, 0.84). There was significant heterogeneity between trials.

Conclusions: RDN safely reduces ambulatory and office systolic blood pressure/diastolic blood pressure versus a sham procedure in the presence and absence of antihypertensive medications.

Citing Articles

NLRP3 inflammasome in cardiovascular diseases: an update.

Mo B, Ding Y, Ji Q Front Immunol. 2025; 16:1550226.

PMID: 40079000 PMC: 11896874. DOI: 10.3389/fimmu.2025.1550226.


Novel role of GRK2 in isoprenaline-induced activation of Na/H exchanger 3 independent of β2-adrenergic receptor signaling.

Dai Y, Wen H, Lai X, Huang J, Li J Mol Biol Rep. 2025; 52(1):218.

PMID: 39932653 DOI: 10.1007/s11033-025-10326-4.


Hypertension approaches and recent SGLT2i studies.

Bloomgarden Z J Diabetes. 2024; 16(11):e70034.

PMID: 39582313 PMC: 11586533. DOI: 10.1111/1753-0407.70034.


Response of Blood Pressure to Renal Denervation Is Not Associated With Genetic Variants.

Delles C, Schmieder R, Daly R, Kannenkeril D, Bosch A, Lauder L Hypertension. 2024; 82(1):118-125.

PMID: 39569514 PMC: 11654447. DOI: 10.1161/HYPERTENSIONAHA.124.23393.

References
1.
Azizi M, Saxena M, Wang Y, Jenkins J, Devireddy C, Rader F . Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023; 329(8):651-661. PMC: 9975904. DOI: 10.1001/jama.2023.0713. View

2.
Bohm M, Kario K, Kandzari D, Mahfoud F, Weber M, Schmieder R . Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020; 395(10234):1444-1451. DOI: 10.1016/S0140-6736(20)30554-7. View

3.
Altman D, Bland J . Interaction revisited: the difference between two estimates. BMJ. 2003; 326(7382):219. PMC: 1125071. DOI: 10.1136/bmj.326.7382.219. View

4.
Sharp A, Tunev S, Schlaich M, Lee D, Finn A, Trudel J . Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model. J Hypertens. 2022; 40(10):2068-2075. PMC: 9451943. DOI: 10.1097/HJH.0000000000003236. View

5.
Azizi M, Sharp A, Fisher N, Weber M, Lobo M, Daemen J . Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. Circulation. 2023; 149(10):747-759. DOI: 10.1161/CIRCULATIONAHA.123.066941. View